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Background: Epidemiological studies have found a U-shaped relationship between serum phosphorus and
cardiovascular disease (CVD). The mechanism(s) behind such a relationship are poorly understood. Phosphorus
(P) is reported to improve insulin sensitivity, which is involved in lipid metabolism, and thus we were interested in
determining the impact of phosphorus ingestion on postprandial lipemia, a recognized CVD risk factor.
Findings: A within–subject study design was conducted, whereby 8 healthy male subjects received a high fat meal
(330Kcal; 69% energy from fat; 35 mg of phosphorus) with placebo or phosphorus (500 mg) in a random order.
Postprandial blood samples (~10 ml) were collected every hour for 6 hours after meal ingestion. Changes in different
parameters were analyzed using a 2-factor repeated-measure ANOVA. In the phosphorus (P) supplemented group,
postprandial serum P increased (p = 0.00), while changes in insulin, non-esterified fatty acids (NEFA) and triglyceride
(TG) were not significantly different than that of placebo. Concurrently, phosphorus supplementation increased
postprandial concentrations of apolipoprotein B48 (ApoB48) (p < 0.05) and decreased that of apolipoprotein B100
(ApoB100) (p < 0.05).
Conclusions: Phosphorus supplementation (500 mg) of the meal seems to alter the different components of
postprandial lipemia. These findings highlight the potential role of phosphorus in CVD.
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Postprandial lipemia (PPL) is characterized by the accu-
mulation of triglyceride-rich lipoproteins (TRLs) and
their partially hydrolyzed products that results from the
absorption of digested dietary lipids in the form of chylo-
microns (CM) that contain ApoB48 and/or increased hep-
atic production of very low density lipoproteins (VLDL)
that contain ApoB100 [1]. Elevated serum levels of TRLs
or their components (TG, ApoB48 and ApoB100) are re-
ported to be associated with atherosclerosis and cardio-
vascular disease (CVD) [2] and to be predictors of their
future occurrence [3]. In addition, high TG predisposes
to other atherogenic risk factors such as low high density
lipoproteins (HDL), high small dense low density lipopro-
tein (LDL) and insulin resistance [4,5]. Hence, PPL reduc-
tion is of vital clinical importance and the elucidation of
factors able to regulate it can have significant clinical* Correspondence: omar.obeid@aub.edu.lb
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unless otherwise stated.implications for the prevention of atherosclerosis and
CVD, particularly as humans are in the postprandial state
for a large part of the day. PPL is known to be affected by
several factors including diet, lifestyle, genetics, obesity,
and insulin resistance [6]. Dietary factors include the
amount and type of fat consumed as well as other compo-
nents of a meal including carbohydrate, protein, alcohol
and fiber content [6]. While data on the effect of micronu-
trients on PPL are limited, magnesium has been reported
to improve postprandial lipemia [7].
Both low and high levels of serum phosphorus (P) have
been associated with increased risk of CVD [8]. Increased
serum P levels have been implicated in CVD morbidity
and mortality among subjects with normal and abnormal
kidney function [8,9]. The biological mechanism(s) of such
an effect are poorly understood, though high P levels were
reported to induce vascular calcification and endothelial
dysfunction [10,11]. In contrast, low serum P is known to
be associated with insulin resistance and impaired glucose
tolerance [8], while addition of P to an oral glucose load
improves insulin sensitivity [12]. In line with that, serum PLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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syndrome a known risk factor for CVD [13].
It was hypotheses that P addition to a meal would
stimulate lipid clearance from circulation due to its cap-
acity to increase insulin sensitivity. Therefore, the nature
of the relation between serum phosphate and CVD risk
factors is far from clear, which triggered our interest to
investigate the effect of P ingestion on insulin and PPL,
particularly NEFA, TG, ApoB48 and ApoB100.
Methods
A total of 8 healthy male subjects participated in the study,
since lipid profile is known to be affect by the sex steroids
[14]. They had no history of any chronic diseases, includ-
ing renal, endocrine, hepatic, thyroid, or cardiac disorder.
They were not taking any medication that affects body
weight, glucose or lipid metabolism. The study protocol
was approved by the Institutional Review Board (IRB) at
the American University of Beirut. Written informed con-
sent was obtained from all the subjects. The baseline char-
acteristics of the participants are shown in Table 1.
Experimental protocol
The study employed a within–subject design where each
participant served as his own control. Experimental ses-
sions were scheduled in random order and were separated
by a washout period of a minimum of 1 week. Following
12–14 hours overnight fast, a Teflon catheter was inserted
into the antecubital vein in the morning and subjects were
asked to remain in a semi recumbent position during the
experimental session. They were allowed bathroom access
and provided with drinking water, when needed. A baselineTable 1 Main characteristics of the subjects participating
in the study
Mean ± SEM
Age (years) 19.25 ± 0.41
BMI (kg/m2) 22.72 ± 0.94
Waist circumference (cm) 72.63 ± 3.22
Total phosphate (mg/dl) 3.950 ± 0.18
Glucose (mg/dl) 79.75 ± 1.73
Insulin (μIU/ml) 9.290 ± 1.38
Triglycerides (mg/dl) 100.9 ± 12.9
NEFA (mmol/dl) 0.630 ± 0.12
Apo-B48 (ng/ml) 630.1 ± 21.1
Apo-B100 (μg/ml) 708.9 ± 47.5
Total cholesterol (mg/dl) 142.0 ± 6.38
LDL (mg/dl) 83.70 ± 4.76
HDL (mg/dl) 38.13 ± 2.81
Values are the mean ± SEM. BMI, Body Mass Index; NEFA, Non Esterified Fatty
Acids; Apo-B48, apolipoprotein B48; apo-B100, apolipoprotein B100; LDL,
Low-Density Lipoprotein; HDL, High-Density Lipoprotein.blood sample (10 ml) was collected before receiving the
treatments (meal with the allocated supplement) which
was ingested within 10 minutes. The meal was composed
of bread roll (25 g), unsalted spreadable butter (30 g), and
jam (14 g) with tablets containing either 500 mg phos-
phorus or a placebo (Nutricap Labs, Farmingdale, NY,
USA). The meal provided 330 Kcal; (69% from fat, 28%
from carbohydrate and 3% from protein) and about 35 mg
of phosphorus. The subjects were blinded on the content
of the tablets. Postprandial blood samples (~10 ml) were
taken every hour, for 6 hours after meal ingestion. Blood
samples were centrifuged for 15 minutes at 3500 RPM at
3°C for serum and plasma separation. Sample aliquots
were stored at −80°C until analysis.
Laboratory procedures
Concentrations of glucose, triglycerides, and total phos-
phate were measured using an enzymatic colorimetric
method on Vitros DT 60 II Chemistry System (Ortho-
Clinical Diagnostics; Johnson & Johnson, New York, NY).
Serum insulin levels were analyzed using ELISA kits
(Diametra Millipore, USA). Non-esterified free fatty acids
concentrations were determined by enzymatic colorimet-
ric method (Wako Chemicals, GmbH, Neuss, Germany).
ELISA kits were used to analyze plasma ApoB100 (Immuno-
Biological Laboratories Co., Ltd, Japan) and serum ApoB48
concentrations (Shibayagi Co., Ltd., Japan).
Statistical analysis
Data in Table 1 represent the values derived from the first
experimental session and these were almost identical to
those in the second session. Changes in different parame-
ters were analyzed using 2-factor repeated-measures
ANOVA. The 2 explanatory variables being first the type
of treatment (P or placebo) which was given repeatedly to
the same subjects, and second the time of assessment of
the dependent variable, i.e. the change in each parameter
like Apo B48, at every hour after any intervention. The
level of significance alpha was fixed at 0.05.
Data in tables represent the means ± SEM. P-values <
0.05 were considered statistically significant.
Findings
All subjects had normal BMI, waist circumference, as well
as normal levels of fasting serum glucose, insulin, HOMA,
TG, Total cholesterol, LDL and HDL levels (Table 1). Post-
prandial changes (Figure 1) in serum P were significantly
different according to time (p < 0.000) and treatments
(p < 0.001), while that of NEFA was significant according
to time (p < 0.000) only. The pattern of changes in serum
insulin and TG level varied slightly but not significantly
between the two treatments.
Ingestion of P with meal resulted in a significant re-




























































































































































Figure 1 Difference from baseline (Δ) of postprandial: serum phosphate (A), insulin (B), triglycerides (C), NEFA (D), apoB100 (E), and
plasma apo-B48 (F) after the ingestion of the high fat meal with placebo (diamond) or with 500 mg P (square). Two-factor
repeated-measures analysis of variance (Phosphorus, Time and their Interaction, blue diamond; red square).
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ApoB48 were significantly different according to time
(p < 0.01). The addition of P to meal was able to prolonged
the increase in postprandial ApoB48 levels and this re-
sulted in a statistical significant difference between the
two treatments (p < 0.05).
Discussion
Our study showed that phosphorus addition to a high
fat meal increases the postprandial level of ApoB48 andconcomitantly decrease that of ApoB100 of healthy male
subjects. Phosphorus is known to be involved in carbohy-
drate, fat, protein and energy metabolism and is a compo-
nent of several compounds including phospholipids. The
fact that P improves insulin sensitivity implicates it in
PPL since the production, clearance and degradation of
TRLs are known to be affected by insulin [4,15]. Insulin
resistance and diabetes stimulate the production of both
intestinal (chylomicrons) and hepatic (VLDL) derived li-
poproteins, and decrease their catabolic and clearance
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NEFA between treatment groups argues against their
involvement in the observed ApoB100 and ApoB48
changes.
The similarity between treatments in serum ApoB48
during the first two hours implies that P ingestion did
not affect fat absorption but rather extended the release
of ApoB48 into circulation. In the P ingested group, the
pattern of postprandial changes in serum P resembles
that of ApoB48 (r = 0.407, p = 0.002) and this may raise
the possibility of the involvement of increased intestinal
P availability with ApoB48 production, especially since P
is known to be well absorbed along the entire intestinal
tract [16]. The similarity in postprandial insulin levels
between treatments does not support a difference in
chylomicron (ApoB48) clearance. On the other hand, the
sustained increase in ApoB48 concentrations is believed
to augment its atherogenic potential, especially since post-
prandial arterial lipoprotein retention prefers ApoB48 as
compared to ApoB100 containing lipoproteins [17]. Post-
prandial VLDL production is known to start 3–4 hour
post meal ingestion and thus the modest reduction in
ApoB100 (component of VLDL and LDL) may imply that
P content of the meal altered VLDL and LDL clearance.
Such alteration may partially be related to a competition
with chylomicron for clearance, especially since postpran-
dial ApoB48 of the P ingested group was maintained for
longer duration. It is worth mentioning that in the USA,
daily phosphorus intake (mean ± SE) was reported to be
1277 ± 12.8 mg [18] and is mainly derived from animal
sources, especially dairy products and meats. A 500 mg of
phosphorus can be obtained from consuming about
500 ml of milk, 150 g of cheese, 300 g of meat or 5000 ml
of carbonated cola beverages. Our study has limitations,
mainly the small sample size. Even though the cross over
design may be more suitable than parallel group trials for
a small sample size ensuring comparability of subjects to
themselves and thus less variability, we think that a study
with a bigger sample size would be needed to make stron-
ger statistical and clinical implications. At the same time,
a study is needed to assess the impact of P ingestion on
women. Another possible limitation is the absence of
blinding of the researchers, but this may not be as import-
ant as the main outcome was objective measurements of
biologic parameters.
In conclusion, in contrast to our proposed hypothesis, in-
creased P content of a high fat meal was not able to stimu-
late lipid clearance from circulation. However, this study
shows that P ingestion was able to manipulate several com-
ponents of PPL, through the reduction in ApoB100 and the
increase in ApoB48. The impact of such manipulation on
the development of atheroma is not clear since both are in-
volved in this process, although ApoB48 has a higher
atherogenic effect.Abbreviations
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